INmune Bio (NASDAQ: INMB), an immunology company focused on
developing treatments that harness the patient’s innate immune system to fight
disease, recently reported financial results for the second quarter ended June
30, 2019 (http://ibn.fm/shHin).
An article discussing the company reads, “Apart from announcing strategic
developments, INmune Bio also presented its most important financial results
for the second quarter. Net loss attributable to common stockholders for the
second quarter was $0.4 million, in comparison to $6.2 million for the same
quarter of 2018. Research and development expenditure remained unchanged at
$0.3 million. The total research and development expenditure was $0.6 million,
but it was partially offset by a $0.3 million Alzheimer’s Association grant. .
. . As of June 30, INmune Bio had cash and cash equivalents of $9.4 million
with no debt. In May 2019, INmune closed a private placement of nearly $4.7
million. As of August 9, INmune Bio has 10.8 million common and 13.9 million
fully diluted shares outstanding.”
To view the full article, visit http://ibn.fm/sT7d6
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB),
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product platforms:
two products that re-engineer the patient’s innate immune system’s response to
cancer and one product to treat neuroinflammation that is currently focused on
Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that
primes the patient’s NK cells to attack minimal residual disease, the remaining
cancer cells that are difficult to detect, which often cause relapse. INB03
inhibits myeloid derived suppressor cells (“MDSC”), which often cause
resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595
targets neuroinflammation, which causes microglial activation and neuronal cell
death. INmune Bio’s product platforms utilize a precision medicine approach for
the treatment of a wide variety of hematologic malignancies, solid tumors and
chronic inflammation. To learn more, please visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
